Literature DB >> 27073638

Clinical significance of serum laminin levels in patients with lung cancer.

Faruk Tas1, Elif Bilgin1, Didem Tastekin1, Kayhan Erturk1, Derya Duranyildiz1.   

Abstract

Cellular adhesion molecules are considered useful markers in the diagnosis and prognosis of several types of malignant tumors. Laminin, a major structural component of the basement membrane, is a strong promoter of cell adhesion, migration, differentiation and proliferation via integrins and other cell surface receptors. The present study aimed to evaluate the clinical significance of the serum level of laminin in lung cancer patients. A total of 80 patients with lung cancer were enrolled in the study. The serum laminin level was measured by the solid-phase sandwich enzyme-linked immunosorbent assay method. The median age was 58.5 years (range, 36-80 years). The majority of the patients had non-small cell lung carcinoma (85%) and stage IV disease (56%). The baseline serum laminin levels of patients were significantly higher compared to the control group (median values 1.17 vs. 0.78 ng/ml, P=0.033). However, the clinical variables, such as age, gender, histology, stage of disease and response to chemotherapy, were not correlated with serum laminin level (P>0.05). Similarly, serum laminin level was not associated with survival (P=0.68). In conclusion, the serum level of laminin may have a diagnostic value in lung cancer patients. However, its predictive and prognostic roles were not observed.

Entities:  

Keywords:  diagnostics; laminin; lung cancer; serum

Year:  2016        PMID: 27073638      PMCID: PMC4812179          DOI: 10.3892/br.2016.612

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  6 in total

Review 1.  The new World Health Organization classification of lung tumours.

Authors:  E Brambilla; W D Travis; T V Colby; B Corrin; Y Shimosato
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

2.  Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer.

Authors:  Jolanta Szelachowska; Michal Jelen; Jan Kornafel
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

3.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

4.  Laminin and type VII collagen distribution in different types of human lung carcinoma: correlation with expression of keratins 14, 16, 17 and 18.

Authors:  R H Wetzels; H E Schaafsma; I M Leigh; E B Lane; S M Troyanovsky; S S Wagenaar; G P Vooijs; F C Ramaekers
Journal:  Histopathology       Date:  1992-04       Impact factor: 5.087

Review 5.  The new lung cancer staging system.

Authors:  Frank C Detterbeck; Daniel J Boffa; Lynn T Tanoue
Journal:  Chest       Date:  2009-07       Impact factor: 9.410

6.  Serum laminin P1 in small cell lung cancer: a valuable indicator of distant metastasis?

Authors:  T Nakano; N Iwahashi; J Maeda; T Hada; K Higashino
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

  6 in total
  3 in total

1.  [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].

Authors:  J Gao; L Zhang; K Peng; H Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-06-20

Review 2.  The Double Engines and Single Checkpoint Theory of Endometriosis.

Authors:  Che-Fang Hsu; Aye Aye Khine; Hsuan-Shun Huang; Tang-Yuan Chu
Journal:  Biomedicines       Date:  2022-06-14

3.  Downregulation of TRIM28 inhibits growth and increases apoptosis of nude mice with non‑small cell lung cancer xenografts.

Authors:  Lei Liu; Lei Zhang; Jianping Wang; Xuerong Zhao; Qian Xu; Yanjie Lu; Yanzhen Zuo; Long Chen; Jia Du; Yali Lian; Qin Zhang
Journal:  Mol Med Rep       Date:  2017-11-03       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.